Compare Stocks

Enter up to five stock symbols separated by a comma or space (ex. BAC,WFC,JPM,LON:BARC).
Date Range: 

 Ultragenyx PharmaceuticalJazz PharmaceuticalsDr. Reddy's LaboratoriesMirati TherapeuticsZai Lab
SymbolNASDAQ:RARENASDAQ:JAZZNYSE:RDYNASDAQ:MRTXNASDAQ:ZLAB
Price Information
Current Price$103.48$161.40$63.92$170.17$132.63
52 Week RangeBuyBuyBuyBuyBuy
MarketRank™
Overall Score1.62.11.31.61.4
Analysis Score4.33.41.53.32.5
Community Score3.33.42.12.92.3
Dividend Score0.00.01.70.00.0
Ownership Score0.01.70.01.71.7
Earnings & Valuation Score0.61.91.30.00.6
Analyst Ratings
Consensus RecommendationBuyBuyBuyBuyBuy
Consensus Price Target$131.20$185.88$70.00$218.57$159.00
% Upside from Price Target26.79% upside15.17% upside9.51% upside28.44% upside19.88% upside
Trade Information
Market Cap$6.93 billion$9.09 billion$10.63 billion$8.62 billion$11.75 billion
Beta2.191.080.411.640.95
Average Volume459,911726,677212,135429,490421,993
Sales & Book Value
Annual Revenue$103.71 million$2.16 billion$2.32 billion$3.34 million$12.98 million
Price / Sales66.804.214.592,579.76905.24
CashflowN/A$21.99 per share$3.38 per shareN/AN/A
Price / CashN/A7.3418.92N/AN/A
Book Value$11.32 per share$54.99 per share$12.41 per share$9.67 per share$5.07 per share
Price / Book9.142.945.1517.6026.16
Profitability
Net Income$-402,730,000.00$523.37 million$259 million$-213,260,000.00$-195,070,000.00
EPS($7.36)$14.60$2.79($5.69)($3.03)
Trailing P/E RatioN/A50.9152.83N/AN/A
Forward P/E RatioN/A10.5626.30N/AN/A
P/E GrowthN/A4.64N/AN/AN/A
Net Margins-119.19%7.86%8.23%N/AN/A
Return on Equity (ROE)-50.69%20.16%16.33%-60.01%N/A
Return on Assets (ROA)-26.87%10.85%10.79%-54.21%N/A
Dividend
Annual PayoutN/AN/A$0.27N/AN/A
Dividend YieldN/AN/A0.42%N/AN/A
Three-Year Dividend GrowthN/AN/A6.19%N/AN/A
Payout RatioN/AN/A9.68%N/AN/A
Years of Consecutive Dividend GrowthN/AN/AN/AN/AN/A
Debt
Debt-to-Equity RatioN/A0.55%0.04%N/AN/A
Current Ratio4.33%3.98%1.72%8.84%8.57%
Quick Ratio4.26%3.84%1.20%8.84%8.46%
Ownership Information
Institutional Ownership PercentageN/A95.67%12.89%94.92%81.32%
Insider Ownership Percentage8.20%4.60%2.00%4.10%N/A
Miscellaneous
Employees8931,94021,6501991,194
Shares Outstanding66.95 million56.33 million166.29 million50.63 million88.59 million
Next Earnings Date5/5/2021 (Estimated)5/4/2021 (Estimated)5/19/2021 (Estimated)5/6/2021 (Estimated)N/A
OptionableOptionableOptionableOptionableOptionableOptionable
SourceHeadline
Zai Lab Limited: Best Price-Positioned Biotech Developer Stock, As Seen By Market-MakersZai Lab Limited: Best Price-Positioned Biotech Developer Stock, As Seen By Market-Makers
seekingalpha.com - April 9 at 3:19 AM
Zai Lab (ZLAB) Chairwoman & CEO Ying Du Sold $14.2 million of SharesZai Lab (ZLAB) Chairwoman & CEO Ying Du Sold $14.2 million of Shares
finance.yahoo.com - April 8 at 12:23 AM
Zai Lab Limited (NASDAQ:ZLAB) CEO Sells $2,948,637.12 in StockZai Lab Limited (NASDAQ:ZLAB) CEO Sells $2,948,637.12 in Stock
americanbankingnews.com - April 7 at 10:46 PM
Insider Selling: Zai Lab Limited (NASDAQ:ZLAB) CEO Sells 50,784 Shares of StockInsider Selling: Zai Lab Limited (NASDAQ:ZLAB) CEO Sells 50,784 Shares of Stock
americanbankingnews.com - April 7 at 10:46 PM
Zai Lab (NASDAQ:ZLAB) Shares Gap Up to $127.69Zai Lab (NASDAQ:ZLAB) Shares Gap Up to $127.69
americanbankingnews.com - April 7 at 11:00 AM
Zai Lab wins China approval for Qinlock to treat fourth-line GISTZai Lab wins China approval for Qinlock to treat fourth-line GIST
bioworld.com - April 2 at 12:23 PM
Kai-Xian Chen Sells 4,302 Shares of Zai Lab Limited (NASDAQ:ZLAB) StockKai-Xian Chen Sells 4,302 Shares of Zai Lab Limited (NASDAQ:ZLAB) Stock
americanbankingnews.com - March 30 at 10:54 PM
Analysts Say You Should Go Buying Zai Lab Limited (NASDAQ:ZLAB)Analysts Say You Should Go Buying Zai Lab Limited (NASDAQ:ZLAB)
stocksregister.com - March 27 at 9:31 AM
First Week of ZLAB May 21st Options TradingFirst Week of ZLAB May 21st Options Trading
nasdaq.com - March 22 at 2:01 PM
7 Biotech Stocks With Catalysts That Go Far Beyond Covid-19 Vaccines7 Biotech Stocks With Catalysts That Go Far Beyond Covid-19 Vaccines
finance.yahoo.com - March 20 at 8:21 AM
Zai Lab is Now Oversold (ZLAB)Zai Lab is Now Oversold (ZLAB)
nasdaq.com - March 8 at 12:23 PM
Why Amgens $1.9 Billion Takeover Might Only Whet Its Appetite In 2021Why Amgen's $1.9 Billion Takeover Might Only Whet Its Appetite In 2021
finance.yahoo.com - March 4 at 1:25 PM
argenx Reports Full Year 2020 Financial Results and Provides Fourth Quarter Business Updateargenx Reports Full Year 2020 Financial Results and Provides Fourth Quarter Business Update
benzinga.com - March 4 at 1:59 AM
Analysts Are More Bearish On Zai Lab Limited (NASDAQ:ZLAB) Than They Used To BeAnalysts Are More Bearish On Zai Lab Limited (NASDAQ:ZLAB) Than They Used To Be
finance.yahoo.com - March 3 at 10:25 AM
Zai Lab Reaches Analyst Target PriceZai Lab Reaches Analyst Target Price
nasdaq.com - March 2 at 1:09 PM
Zai Lab Limited 2020 Q4 - Results - Earnings Call PresentationZai Lab Limited 2020 Q4 - Results - Earnings Call Presentation
seekingalpha.com - March 1 at 4:32 PM
Zai Lab Announces Financial Results for Second-half and Full-year 2020Zai Lab Announces Financial Results for Second-half and Full-year 2020
finance.yahoo.com - March 1 at 9:48 AM
Zai Lab earnings: heres what to expectZai Lab earnings: here's what to expect
markets.businessinsider.com - February 28 at 11:25 PM
ZLAB Mar 2021 165.000 callZLAB Mar 2021 165.000 call
uk.finance.yahoo.com - February 19 at 6:38 PM
Zai Lab to Announce Full-Year 2020 Financial Results on March 1, 2021Zai Lab to Announce Full-Year 2020 Financial Results on March 1, 2021
finance.yahoo.com - February 18 at 9:26 AM
Zai Lab Announces Upcoming Presentations in February Investor ConferencesZai Lab Announces Upcoming Presentations in February Investor Conferences
apnews.com - January 28 at 9:47 AM
3 Chinese Stocks Outperforming NIO in 20213 Chinese Stocks Outperforming NIO in 2021
stocknews.com - January 25 at 7:08 PM
ZLAB December 17th Options Begin TradingZLAB December 17th Options Begin Trading
nasdaq.com - January 19 at 6:13 PM
The ZLAB Paradox: Analysts Bullish But Forecast -23.94% FallThe ZLAB Paradox: Analysts Bullish But Forecast -23.94% Fall
nasdaq.com - January 11 at 9:13 AM
argenx and Zai Lab Announce Strategic Collaboration for Efgartigimod in Greater Chinaargenx and Zai Lab Announce Strategic Collaboration for Efgartigimod in Greater China
finance.yahoo.com - January 6 at 6:29 PM
DateCompanyBrokerageAction
3/1/2021Ultragenyx PharmaceuticalStifel NicolausInitiated Coverage
2/16/2021Ultragenyx PharmaceuticalSVB LeerinkBoost Price Target
2/12/2021Ultragenyx PharmaceuticalWedbushBoost Price Target
2/12/2021Ultragenyx PharmaceuticalPiper SandlerBoost Price Target
2/12/2021Ultragenyx PharmaceuticalBarclaysBoost Price Target
2/12/2021Ultragenyx PharmaceuticalJPMorgan Chase & Co.Downgrade
1/25/2021Ultragenyx PharmaceuticalCredit Suisse GroupBoost Price Target
1/11/2021Ultragenyx PharmaceuticalRobert W. BairdBoost Price Target
11/24/2020Ultragenyx PharmaceuticalEvercore ISIReiterated Rating
11/12/2020Ultragenyx PharmaceuticalBank of AmericaDowngrade
10/29/2020Ultragenyx PharmaceuticalCanaccord GenuityBoost Price Target
10/28/2020Ultragenyx PharmaceuticalTruistBoost Price Target
10/28/2020Ultragenyx PharmaceuticalMorgan StanleyBoost Price Target
3/8/2021Jazz PharmaceuticalsUBS GroupBoost Price Target
2/24/2021Jazz PharmaceuticalsCowenBoost Price Target
2/24/2021Jazz PharmaceuticalsJefferies Financial GroupBoost Price Target
2/5/2021Jazz PharmaceuticalsHC WainwrightBoost Price Target
11/3/2020Jazz PharmaceuticalsWells Fargo & CompanyBoost Price Target
11/3/2020Jazz PharmaceuticalsRoyal Bank of CanadaBoost Price Target
2/3/2021Dr. Reddy's LaboratoriesInvestecUpgrade
4/21/2020Dr. Reddy's LaboratoriesNomura InstinetReiterated Rating
1/9/2020Dr. Reddy's LaboratoriesCitigroupUpgrade
7/1/2019Dr. Reddy's LaboratoriesMacquarieUpgrade
6/20/2019Dr. Reddy's LaboratoriesDeutsche Bank AktiengesellschaftInitiated Coverage
2/4/2019Dr. Reddy's LaboratoriesCL KingUpgrade
3/8/2021Mirati TherapeuticsOppenheimerLower Price Target
12/8/2020Mirati TherapeuticsJMP SecuritiesInitiated Coverage
11/10/2020Mirati TherapeuticsGuggenheimDowngrade
10/26/2020Mirati TherapeuticsThe Goldman Sachs GroupBoost Price Target
10/21/2020Mirati TherapeuticsBMO Capital MarketsBoost Price Target
10/8/2020Mirati TherapeuticsCSFBBoost Price Target
9/4/2019Zai LabChina Renaissance SecuritiesInitiated Coverage
(Data available from 4/11/2018 forward. View 10+ years of historical ratings with our analyst ratings screener.)
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security. Learn more.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research. As a bonus to opt-ing into our email newsletters, you will also get a free subscription to the Liberty Through Wealth e-newsletter. You can opt out at any time.